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after one cycle of rituximab (follow-up periods: 65, 27 and
13 months). One patient with BP achieved a partial remission
and one patient with antilaminin-c1 pemphigoid, both treat-
ment refractory, achieved full remission after one cycle of rit-
uximab. Two patients with MMP improved after CD20-
depleting therapy: one showed a full remission after two
cycles, the other patient showed a partial remission after one
cycle of therapy. Three patients had a further progression of
the disease with a continued inflammation of the ocular
mucous membranes despite therapy.
A follow-up assessment of B-cell levels was performed in
six patients by detecting CD19+ and CD20+ in peripheral
blood via fluorescence-activated cell sorting analysis. We
observed a B-cell depletion after rituximab treatment for
97  73 months.
Tolerability was good in the majority of patients (20 of
22). Two adverse events were observed during B-cell-deplet-
ing therapy. One patient developed a rituximab-induced
alveolitis 4 days after the second infusion of rituximab,
which was treated with intravenous antibiotics and resolved
during therapy. In another patient, the second infusion was
stopped due to the development of a metallic taste in the
mouth.
Our data show that B-cell ablative treatment is safe and
effective in controlling recalcitrant courses of autoimmune
blistering skin diseases. Moreover, we observed long-term
remission in 15 of 22 patients, with an observational follow-
up phase of up to 48 months, which is longer than the fol-
low-up phase used in previous studies (Kanwar and Vinay7 up
to 37 months and Gregoriou et al.8 up to 42 months). Our
small data series suggests that patients with PV and PF seem
more likely to respond to B-cell depletion than patients with
MMP. Furthermore, B-cell depletion can also be considered as
a treatment option for patients diagnosed with treatment-
refractory BP and antilaminin-c1 pemphigoid, as we observed
good clinical efficacy in these patients as well.
Cumulatively, our data support previous reports on clinical
efficacy of a B-cell-targeted treatment in different subsets of
autoimmune bullous skin disease. Our findings also support
the need for a prospective clinical trial to prove that such treat-
ment is not only efficacious and tolerable but also long-
lasting. The long remission period strongly suggests that ritux-
imab therapy is a possible curative approach, as the concomi-
tant immunosuppressive medication was reduced and even
stopped for several patients. Apparently long-lived plasma
cells, which are thought to play a role in many immunological
diseases9,10 and are not affected by immunosuppressive
agents, do not seem to play a central role in the pathogenesis
of autoimmune blistering diseases.
D . TOMS I T Z
R . ST E FAN I AK
M. WORM
Klinik f€ur Dermatologie, Venerologie und
Allergologie, Charite Universit€atsmedizin




1 Harmann KE, Albert S, Black MM. Guidelines for the management
of pemphigus vulgaris. Br J Dermatol 2003; 149:926–37.
2 Venning VA, Taghipour K, Mohd Mustapa MF et al. British
Association of Dermatologists’ guidelines for the management of
bullous pemphigoid 2012. Br J Dermatol 2012; 167:1200–14.
3 Kasperkiewicz M, Eming R, Behzad M et al. Efficacy and safety
of rituximab in pemphigus: experience of the German Regis-
try of Autoimmune Diseases. J Dtsch Dermatol Ges 2012; 10:
727–31.
4 Shetty S, Ahmed AR. Critical analysis of the use of rituximab in
mucous membrane pemphigoid: a review of the literature. J Am
Acad Dermatol 2013; 68:499–506.
5 Shetty S, Ahmed AR. Treatment of bullous pemphigoid with ritux-
imab: critical analysis of the current literature. J Drugs Dermatol
2013; 12:672–7.
6 Smolen JS, Keystone EC, Emery P et al. Consensus statement on the
use of rituximab in patients with rheumatoid arthritis. Ann Rheum
Dis 2007; 66:143–50.
7 Kanwar AJ, Vinay K. Rituximab in pemphigus. Indian J Dermatol Vene-
reol Leprol 2012; 78:671–6.
8 Gregoriou S, Giatrakou S, Theordoropoulos K et al. Pilot study of
19 patients with severe pemphigus: prophylactic treatment with
rituximab does not appear to be beneficial. Dermatology 2014;
228:158–65.
9 Luger EO, Fokuhl V, Wegmann M et al. Induction of long-lived
allergen-specific plasma cells by mucosal allergen challenge. J
Allergy Clin Immunol 2009; 124:819–26.
10 Hoyer BF, Mumtaz IM, Yoshida T et al. How to cope with patho-
genic long-lived plasma cells in autoimmune diseases. Ann Rheum
Dis 2008; 67 (Suppl. 3):iii87–9.
Funding source: none.
Conflicts of interest: none declared.
Paraneoplastic pemphigus associated with
metastatic lymphoepithelioma-like carcinoma
originating from the thyroid gland
DOI: 10.1111/bjd.13334
DEAR EDITOR, Paraneoplastic pemphigus (PNP) is a rare, life-
threatening, autoimmune, mucocutaneous blistering disease
associated with underlying neoplasia.1 A previous review of
163 patients with PNP revealed that the neoplasms commonly
associated with PNP are lymphoproliferative tumours, includ-
ing non-Hodgkin lymphoma (386%), chronic lymphocytic
leukaemia (184%), Castleman disease (184%) and benign
thymoma (55%). Overall, 16% of PNP cases had nonhaema-
tological neoplasms, including tumours with either epithelial
(86%) or mesenchymal (62%) origin.2 Lymphoepithelioma-
like carcinoma (LELC) describes a group of tumours with his-
tological features identical to undifferentiated nasopharyngeal
epithelial tumours that occur outside the nasopharynx.3
Although LELC has been observed in many organs, primary
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LELC of the thyroid gland is extremely rare. Cases of LELC of
the thyroid gland have been reported using many different
terms, such as intrathyroidal epithelial thymoma, carcinoma of
the thyroid showing thymoma-like features and carcinoma
showing thymus-like differentiation (CASTLE).4 Here, we
report a case of PNP associated with primary LELC of the
thyroid gland.
In June 2013, a 59-year-old Korean woman visited our
department with a 1-month history of progressive flaccid blis-
ters and erosions on the whole body (Fig. 1a). The patient
also presented with painful erosions on the oral and genital
mucosae (Fig. 1b). She previously underwent a total thyroid-
ectomy in 2001 due to LELC of the thyroid gland. One year
later, a unilateral radical neck dissection was performed due to
a recurrent neck mass. However, the neck mass recurred in
July 2009 and resection of the salivary gland was performed.
On histopathological examination, high-grade LELC was con-
firmed. In September 2010, intermittent diplopia due to brain
metastasis developed and the patient was treated with gamma
knife radiosurgery. In July 2012, a computerized tomography
scan of the chest showed lung metastasis.
In May 2013, blisters developed over the entire body. A
biopsy specimen revealed subcorneal acantholytic blisters
(Fig. 1c). Direct immunofluorescence showed IgG deposition
along the cell surfaces of keratinocytes (Fig. 2a). Indirect
immunofluorescence (IIF) using human skin substrates
showed IgG antibodies binding to the surface of keratinocytes
at a titre of 1 : 160. IIF using guinea pig urinary bladder
showed a weak deposition of IgG antibodies on the epithelia
(Fig. 2b). Enzyme-linked immunosorbent assay (ELISA) for
antidesmoglein (anti-Dsg) 1 antibodies was positive, but Dsg3
ELISA was negative. Novel ELISA of a mammalian recombinant
protein of Desmocollin (Dsc)1–Dsc3 showed negative results.
Immunoblotting analysis using human epidermal extracts
revealed that the patient’s sera reacted with envoplakin
(210 kDa) and periplakin (190 kDa) (Fig. 2c). Based on these
findings, she was diagnosed with PNP associated with meta-
static LELC of the thyroid.
The patient was treated with intravenous dexamethasone
(10 mg) and intravenous immunoglobulin (04 g kg1 for
5 days), followed by three weekly administrations of ritux-
imab at a dose of 500 mg (375 mg m2). Two months later,
the cutaneous lesions cleared but oral lesions persisted.
Despite an improvement in the cutaneous lesions, the patient
died of multiple distant metastasis of LELC in September
2013.
The patient was initially thought to have pemphigus foliac-
eus, because of subcorneal acantholytic blisters and positive
(a) (b)
(c)
Fig 1. Clinical and histopathological findings. (a) Flaccid blisters and erosions on the whole body. (b) Severe erosions and haemorrhagic crusts on
the oral mucosa. (c) Subcorneal acantholytic blisters containing many neutrophils (9 100).
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ELISA results only for anti-Dsg1 antibodies. However, severe
stomatitis, immunoblotting results with positive reactivity to
both envoplakin and periplakin and the presence of underly-
ing neoplasm confirmed the diagnosis of PNP.
Although the majority of patients with PNP reportedly
exhibit circulating anti-Dsg3 antibodies, which play a patho-
genic role in blister formation, cases of PNP with only anti-
Dsg1 antibodies on ELISA have also been reported.5 The
pathomechanisms of oral lesions in PNP remain unclear.
They may be more complex than those for classic pemphigus
vulgaris, because PNP produces autoantibodies against multi-
ple antigens, including plakin family proteins, Dsgs and Dscs.
Additionally, cell-mediated immune responses may also dam-
age mucosal epithelia.6 It is plausible that mucosal damage
due to cellular immune response caused severe oral lesions
in our patient, because the patient had only anti-Dsg1 anti-
bodies.
To our knowledge, this is the first case of PNP associated
with metastatic LELC originating from the thyroid gland. Pri-
mary LELC of the thyroid is a rare malignant neoplasm of the
thyroid, showing architectural resemblance to thymic epithe-
lial tumours. LELC of the thyroid is thought to be derived
from ectopic thymic tissue or embryonic thymic rest in, or
adjacent to, the thyroid.7 Thirty percent of cases exhibit nodal
metastasis, but the prognosis is more favourable than for squa-
mous cell carcinoma or anaplastic carcinoma of the thyroid.7,8
In general, the course of PNP does not develop in parallel
with that of the underlying neoplasm. However, some cases
of PNP-associated benign tumours, such as thymoma and
Castleman disease, reportedly show favourable prognosis after
tumour resection.1,9
Although LELC of the thyroid is reported to have a better
prognosis than thymic LELC, which is a subtype of high-grade
thymic carcinoma, our patient showed multiple brain and
lung metastases, which led to a fatal outcome. This case
exhibited a rarely aggressive form of LELC of the thyroid, and
suggested that LELC of the thyroid gland can be considered to
be a PNP-associated neoplasm.
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Fig 2. Immunological findings. (a) Cell surface deposition of IgG shown on direct immunofluorescence. (b) A weakly positive IgG deposition on
the epithelia of guinea pig urinary bladder shown on indirect immunofluorescence. (c) The results of immunoblotting analysis using human
epidermal extracts. Control pemphigus vulgaris (PV) serum reacted with the 160-kDa anti-Desmoglein (Dsg) 1 and 130-kDa Dsg3 (lane 1);
control bullous pemphigoid (BP) serum reacted with the 230-kDa BP230 and the 180-kDa BP180 (lane 3); control paraneoplastic pemphigus
(PNP) serum and the patient serum reacted strongly with the 210-kDa envoplakin and the 190-kDa periplakin (lanes 2 and 4).
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Acute systemic sarcoidosis complicating
ustekinumab therapy for chronic plaque
psoriasis
DOI: 10.1111/bjd.13365
DEAR EDITOR, Ustekinumab is a human monoclonal antibody,
which binds to and inhibits interleukin (IL)-12p40, and is
used to treat moderate-to-severe psoriasis and psoriatic arthri-
tis. Sarcoidosis is a systemic granulomatous disease in which
IL-12 levels are elevated in tissues, serum and bronchoalveolar
lavage samples of affected patients.1 Therefore, there is a ratio-
nale for the use of ustekinumab in treating sarcoidosis. The
paradoxical induction of a wide range of autoimmune pro-
cesses such as lupus erythematosus, vasculitis, sarcoidosis and
psoriasis, developing after the initiation of antitumour necrosis
factor (anti-TNF) biological therapies, is increasingly being
reported.2
We present the first reported case, to our knowledge, of
sarcoidosis developing in a patient receiving ustekinumab for
chronic plaque psoriasis (or indeed any indication).
A 42-year-old white female patient with psoriatic arthritis
and severe, difficult-to-control, chronic plaque psoriasis [Psoria-
sis Area and Severity Index (PASI) 193 and Dermatology Life
Quality Index (DLQI) 26 at initiation of therapy] had been trea-
ted with ustekinumab 45 mg subcutaneously for 14 months
when she presented with lethargy, weight loss, night sweats, a
dry cough, dyspnoea and painful lesions on the lower legs. Pre-
vious treatments included phototherapy, ciclosporin, acitretin,
adalimumab and infliximab (both biologics in combination
with methotrexate). Methotrexate 20 mg weekly was continued
while ustekinumab was initiated.
A good response to ustekinumab was elicited with both
PASI and DLQI scores reduced to 1 after 10 months.
Methotrexate was gradually reduced over this period and
eventually stopped. Occasional naproxen was also taken during
this period.
In early January 2013, skin and joint disease remained well
controlled using ustekinumab alone. However, 2 months later
our patient became acutely unwell, as described above. On
examination, tender, erythematous subcutaneous nodules on
the lower legs were present, which were consistent with
erythema nodosum. Investigations revealed normal serum
angiotensin-converting enzyme and adjusted calcium levels.
T-SPOT.TB test for tuberculosis was negative. Chest X-ray
revealed bilateral hilar lymphadenopathy. High-resolution
computed tomography scan of the chest confirmed the
presence of hilar lymphadenopathy with prominent pre-
tracheal and subcarinal adenopathy (Fig. 1a,b) with lung win-
dows revealing pulmonary nodules. Induced sputum samples
and washings following bronchoscopy exhibited no acid-fast
bacilli, with subsequent mycobacterial culture revealing no
growth.
A biopsy from a representative lesion on the lower leg
revealed a septal panniculitis in keeping with erythema nodo-
sum (Fig. 2a). Mediastinoscopy was performed with histology
from an enlarged mediastinal node, revealing a florid, granu-
lomatous lymphadenitis without necrosis (Fig. 2b).
A clinicopathological diagnosis of acute sarcoidosis was
made. Ustekinumab therapy was stopped and systemic steroids
were initiated. This brought about a gradual clinical improve-
ment in our patient, although her cutaneous psoriasis began
to deteriorate.
To our knowledge, this is the first reported case of sarcoid-
osis developing in a patient being treated with ustekinumab
for any condition. A recently published review of the safety
of ustekinumab in the treatment of psoriasis did not include
the induction of autoimmune disease or specifically mention
sarcoidosis.3 Anti-TNF biological agents used in the treatment
of psoriasis are increasingly being utilized in the management
of rheumatic and autoimmune diseases. Paradoxically, these
agents have also been reported to induce a wide range of
these very same conditions, described as a ‘double-edged
sword’ effect of biologics, with over 1500 cases currently
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